Drug Topics spoke with National Community Pharmacists Association CEO B. Douglas Hoey and LucyRx CEO David Blair about what the Consolidated Appropriations Act of 2026 (CAA 2026) could mean for PBM reform, independent pharmacies, and the future of prescription care. The conversation explores new oversight, changing incentives, and the work still needed to create a more transparent system.
For LucyRx, the story emphasizes the need for prescription care built around clear incentives, fair access, and accountability. The coverage highlights an important reality: policy changes can move the industry forward, but lasting progress depends on turning reform into better experiences for employers, pharmacies, and members.
Share